GMAB Stock Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GMAB from our risk checks.
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.28.81 |
52 Week High | kr.42.72 |
52 Week Low | kr.26.32 |
Beta | 0.78 |
1 Month Change | -3.87% |
3 Month Change | 3.48% |
1 Year Change | -31.34% |
3 Year Change | -21.50% |
5 Year Change | 67.50% |
Change since IPO | 704.07% |
Recent News & Updates
Recent updates
Genmab: A Complicated Tale
May 01Genmab Acquires A Missing Piece For Its Pipeline
Apr 16Genmab: Recent Updates Support The Growth Narrative
Feb 21Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Jan 23Genmab: 3 Trends To Track For A Strong 2024 And Beyond
Jan 12Genmab reports Q3 worldwide sales of $2.05B for Darzalex
Oct 18Genmab improves FY 2022 guidance
Aug 08Genmab reports Q2 worldwide net sales of DARZALEX $1.99B
Jul 19Genmab: A Royalty Powerhouse With A Strong Pipeline
Jun 28Genmab: Looking For Growth At A Reasonable Price
Jun 10Genmab: A Biotech Company On The Rise
Mar 12Genmab: Ready For More Growth In 2022
Dec 23Genmab: Monoclonal Antibody Experts, Low Risk Business Model
Aug 18Shareholder Returns
GMAB | US Biotechs | US Market | |
---|---|---|---|
7D | 3.9% | 1.3% | 3.3% |
1Y | -31.3% | 3.0% | 25.0% |
Return vs Industry: GMAB underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: GMAB underperformed the US Market which returned 25% over the past year.
Price Volatility
GMAB volatility | |
---|---|
GMAB Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GMAB has not had significant price volatility in the past 3 months.
Volatility Over Time: GMAB's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,286 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
GMAB fundamental statistics | |
---|---|
Market cap | US$18.70b |
Earnings (TTM) | US$790.25m |
Revenue (TTM) | US$2.57b |
23.7x
P/E Ratio7.3x
P/S RatioIs GMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GMAB income statement (TTM) | |
---|---|
Revenue | kr.17.78b |
Cost of Revenue | kr.411.00m |
Gross Profit | kr.17.37b |
Other Expenses | kr.11.91b |
Earnings | kr.5.47b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 84.64 |
Gross Margin | 97.69% |
Net Profit Margin | 30.74% |
Debt/Equity Ratio | 0% |
How did GMAB perform over the long term?
See historical performance and comparison